SynthesisFrontiers in immunology2025
The prognostic and clinicopathological value of HALP score in non-small cell lung cancer.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients.Medicine · 2026Article
- Early Childhood Caries and Immunonutritional Status in Preschool Children: A Retrospective Comparative Study of the HALP Score and Hematological Biomarkers.Journal of clinical medicine · 2026Article
- Emergency department evaluation of immature granulocytes for complicated acute appendicitis: a retrospective cohort study.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- Prognostic value of the HALP score in patients undergoing emergency surgery for gastroduodenal perforation.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype.Life (Basel, Switzerland) · 2026Article
- HALP Score in Predicting Post-Liver Transplant Outcomes in Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2026Article
- HALP outperforms systemic inflammatory biomarkers for prognosis in locally advanced cervical cancer treated with concurrent chemoradiotherapy.Biomolecules & biomedicine · 2026Article
- Second-Trimester Fibrinogen-to-Albumin Ratio and Platelet Activation Markers Compared with the HALP Score for Predicting Preeclampsia.Diagnostics (Basel, Switzerland) · 2026Article
- Association of the HALP score with baseline and incident physical-cognitive comorbidity and mortality: evidence from the WCHAT and UK Biobank cohorts.Frontiers in public health · 2026Article
- A Machine Learning-Based Nomogram for Predicting Overall Survival in BCLC Stage 0-B Hepatocellular Carcinoma Patients with Low HALP Score.Journal of inflammation research · 2026Article
- HALP, a routine nutrition-inflammation index, and mortality across the cMetS spectrum: NHANES with supportive external cohort evidence.Frontiers in nutrition · 2026Article
- Development and validation of a machine-learning-based triage model incorporating systemic inflammatory, nutritional, coagulation, and tumor marker parameters for identifying baseline distant metastasis in lung cancer.Frontiers in oncology · 2026Article
- Low hemoglobin-albumin-lymphocyte-platelet score as a risk marker for stroke-associated pneumonia in acute ischemic stroke: a retrospective cohort study.Frontiers in neurology · 2026Article
- The predictive value of modified-Naples prognostic score for patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy.Frontiers in immunology · 2026Article
- Association between the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and 28-day mortality in neurocritical care patients: a retrospective cohort study based on the MIMIC-IV database.European journal of medical research · 2025Article
- An Evaluation of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score in Cushing's Syndrome and Mild Autonomous Cortisol Secretion.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The prognostic role of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in non-small cell lung cancer (NSCLC) has been widely reported, but the results remain controversial. Therefore, we aim to evaluate the prognostic and clinicopathological value of the HALP score in NSCLC through a pooled analysis. Methods: We conducted a comprehensive literature search of PubMed, Embase, Web of Science, Cochrane Library, and the ClinicalTrials.gov databases in December 2024 to identify studies evaluating the relationship between the pretreatment HALP score and outcomes in NSCLC patients. Eligible studies included patients treated with surgical resection, chemotherapy, or immunotherapy. The HALP score was calculated using peripheral blood levels of hemoglobin, albumin, lymphocytes, and platelets measured before treatment. Data were extracted and analyzed to determine the association of the HALP score with overall survival (OS), disease/progression/recurrence-free survival (DFS/PFS/RFS), and clinicopathological characteristics. Subgroup and sensitivity analyses were performed to ensure the robustness and reliability of the results. Results: A total of 10 studies involving 7024 patients were included. The results demonstrated that patients with lower pretreatment HALP score had worse OS (hazard ratio [HR] = 1.73, 95% confidence interval [95% CI]: 1.27-2.34, p < 0.001) and DFS/PFS/RFS (HR = 1.86, 95% CI: 1.30-2.64, p < 0.001). The results remained consistent across subgroup analyses based on study characteristics and sensitivity analyses. Additionally, a lower HALP score was significantly associated with age (odds ratio [OR] = 1.43, 95% CI: 1.15-1.78, p = 0.001) and tumor size (OR = 0.54, 95% CI: 0.38-0.76, p < 0.001). Conclusions: The HALP score is a valuable prognostic biomarker for predicting survival outcomes in NSCLC patients. Its ability to integrate multiple aspects of systemic inflammation and nutritional status makes it a promising tool for improving risk stratification and guiding treatment decisions. Future studies should continue to validate this finding in prospective, multicentre trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.